Christos S Mantzoros

List of Publications by Year
in descending order

480	48,042	906 116	2332 199
papers	citations	h-index	g-index

483	483	483	41230
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study. Metabolism: Clinical and Experimental, 2022, 128, 154893.	3.4	33
2	CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study. International Journal of Obesity, 2022, 46, 162-168.	3.4	10
3	Daily transient coating of the intestine leads to weight loss and improved glucose tolerance. Metabolism: Clinical and Experimental, 2022, 126, 154917.	3.4	3
4	Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocrine Reviews, 2022, 43, 507-557.	20.1	39
5	Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers. Hormones, 2022, 21, 91-101.	1.9	8
6	Editorial: Obesity, metabolic phenotypes and COVID-19. Metabolism: Clinical and Experimental, 2022, 128, 155121.	3.4	20
7	Reconstituted HDL-apoE3 promotes endothelial cell migration through ID1 and its downstream kinases ERK1/2, AKT and p38 MAPK. Metabolism: Clinical and Experimental, 2022, 127, 154954.	3.4	12
8	Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial. Metabolism: Clinical and Experimental, 2022, 129, 155157.	3.4	8
9	The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials. Metabolism: Clinical and Experimental, 2022, 129, 155136.	3.4	19
10	Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need. Current Medical Research and Opinion, 2022, 38, 885-888.	1.9	5
11	Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study. Clinical Nutrition, 2022, 41, 1281-1289.	5.0	18
12	Multiphysics and multiscale modeling of microthrombosis in COVID-19. PLoS Computational Biology, 2022, 18, e1009892.	3.2	15
13	Quality of plant-based diets in relation to 10-year cardiovascular disease risk: the ATTICA cohort study. European Journal of Nutrition, 2022, 61, 2639-2649.	3.9	12
14	Dose-related meta-analysis for Omega-3 fatty acids supplementation on major adverse cardiovascular events. Clinical Nutrition, 2022, 41, 923-930.	5.0	8
15	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension, 2022, 79, 1319-1326.	2.7	50
16	MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial. Journal of Neurology, 2022, 269, 4817-4835.	3.6	11
17	Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. Metabolism: Clinical and Experimental, 2022, 132, 155211.	3.4	2
18	A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism: Clinical and Experimental, 2022, 133, 155217.	3.4	238

#	Article	IF	Citations
19	Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity. Metabolism: Clinical and Experimental, 2022, 133, 155237.	3.4	7
20	Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?. Metabolism: Clinical and Experimental, 2022, 136, 155248.	3.4	14
21	PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic doses. Metabolism: Clinical and Experimental, 2022, 134, 155265.	3.4	4
22	Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD). Metabolism: Clinical and Experimental, 2022, 134, 155246.	3.4	12
23	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular Metabolism, 2021, 50, 101049.	6.5	42
24	Effect of the glucagonâ€like peptideâ€1 analogue liraglutide versus placebo treatment on circulating proglucagonâ€derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 489-498.	4.4	14
25	Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf		
26	Mediterranean diet as a nutritional approach for COVID-19. Metabolism: Clinical and Experimental, 2021, 114, 154407.	3.4	63
27	Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis. Heart, 2021, 107, 150-158.	2.9	25
28	Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. International Journal of Molecular Sciences, 2021, 22, 818.	4.1	147
29	Fasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of rewardâ€and attentionâ€related brain centres in response to visual food cues in adults with obesity: A crossâ€sectional functional <scp>MRI</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1202-1207.	4.4	9
30	Integrating blood cell mechanics, platelet adhesive dynamics and coagulation cascade for modelling thrombus formation in normal and diabetic blood. Journal of the Royal Society Interface, 2021, 18, 20200834.	3.4	44
31	Severe insulin resistance syndromes. Journal of Clinical Investigation, 2021, 131, .	8.2	35
32	Adipokines and Metabolic Regulators in Human and Experimental Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2021, 22, 1435.	4.1	6
33	Leptin in Leanness and Obesity. Journal of the American College of Cardiology, 2021, 77, 745-760.	2.8	49
34	Diabetes type 1: Can it be treated as an autoimmune disorder?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 859-876.	5.7	8
35	Vitamin D Status Is Associated With In-Hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients. Mayo Clinic Proceedings, 2021, 96, 875-886.	3.0	62
36	Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of nonâ€alcoholic steatohepatitis. Liver International, 2021, 41, 1853-1866.	3.9	21

#	Article	IF	Citations
37	Diabetes mellitus: 100â€¯years since the discovery of insulin. Metabolism: Clinical and Experimental, 2021, 118, 154737.	3.4	9
38	Maternal Midpregnancy Leptin and Adiponectin Levels as Predictors of Autism Spectrum Disorders: A Prenatal Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4118-e4127.	3.6	5
39	Branched-Chain Amino Acids in relation to food preferences and insulin resistance in obese subjects consuming walnuts: A cross-over, randomized, double-blind, placebo-controlled inpatient physiology study. Clinical Nutrition, 2021, 40, 3032-3036.	5.0	5
40	COVID-19 editorial: mechanistic links and therapeutic challenges for metabolic diseases one year into the COVID-19 pandemic. Metabolism: Clinical and Experimental, 2021, 119, 154769.	3.4	6
41	Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism: Clinical and Experimental, 2021, 119, 154770.	3.4	101
42	Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. International Journal of Molecular Sciences, 2021, 22, 6332.	4.1	15
43	Preparing for the NASH Epidemic: A Call to Action. Diabetes Care, 2021, 44, 2162-2172.	8.6	30
44	Deep transfer learning and data augmentation improve glucose levels prediction in type 2 diabetes patients. Npj Digital Medicine, 2021, 4, 109.	10.9	48
45	Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings. Med, 2021, 2, 814-835.e6.	4.4	12
46	Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. Metabolism: Clinical and Experimental, 2021, 121, 154796.	3.4	3
47	Preparing for the NASH epidemic: A call to action. Obesity, 2021, 29, 1401-1412.	3.0	7
48	Preparing for the NASH Epidemic: A Call to Action. Gastroenterology, 2021, 161, 1030-1042.e8.	1.3	58
49	Incretin-based therapies in 2021 â€“ Current status and perspectives for the future. Metabolism: Clinical and Experimental, 2021, 122, 154843.	3.4	19
50	Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. Metabolism: Clinical and Experimental, 2021, 122, 154781.	3.4	10
51	Preparing for the NASH epidemic: A call to action. Metabolism: Clinical and Experimental, 2021, 122, 154822.	3.4	25
52	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2021, 161, 1657-1669.	1.3	229
53	Serum Follistatin Is Increased in Thyroid Cancer and Is Associated With Adverse Tumor Characteristics in Humans. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2137-e2150.	3.6	8
54	Molecular modelling of novel ADCY3 variantÂpredicts a molecular target for tackling obesity. International Journal of Molecular Medicine, 2021, 49, .	4.0	7

#	Article	IF	Citations
55	Metabolism updates: new directions, techniques, and exciting research that is broadening the horizons. Metabolism: Clinical and Experimental, 2020, 102, 154009.	3.4	3
56	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e390-e400.	3.6	29
57	Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism: Clinical and Experimental, 2020, 103, 154028.	3.4	58
58	GnRH Deficient Patients With Congenital Hypogonadotropic Hypogonadism: Novel Genetic Findings in ANOS1, RNF216, WDR11, FGFR1, CHD7, and POLR3A Genes in a Case Series and Review of the Literature. Frontiers in Endocrinology, 2020, 11, 626.	3.5	20
59	Quantifying Fibrinogen-Dependent Aggregation of Red Blood Cells in Type 2 Diabetes Mellitus. Biophysical Journal, 2020, 119, 900-912.	0.5	31
60	Covid-19 and Disparities in Nutrition and Obesity. New England Journal of Medicine, 2020, 383, e69.	27.0	180
61	Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment. Metabolism: Clinical and Experimental, 2020, 113, 154392.	3.4	7
62	Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism: Clinical and Experimental, 2020, 111, 154318.	3.4	28
63	The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154320.	3.4	68
64	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism: Clinical and Experimental, 2020, 113, 154413.	3.4	45
65	Leptin alters energy intake and fat mass but not energy expenditure in lean subjects. Nature Communications, 2020, 11, 5145.	12.8	48
66	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity, 2020, 28, 1678-1686.	3.0	47
67	The Selective Peroxisome Proliferatorâ€Activated Receptor Gamma Modulator CHSâ€131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. Hepatology Communications, 2020, 4, 1302-1315.	4.3	13
68	The Effect of the Mediterranean Diet on Metabolic Health: A Systematic Review and Meta-Analysis of Controlled Trials in Adults. Nutrients, 2020, 12, 3342.	4.1	119
69	Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism: Clinical and Experimental, 2020, 108, 154262.	3.4	682
70	The Role of Glicentin and Oxyntomodulin in Human Metabolism: New Evidence and New Directions. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3003-e3005.	3.6	19
71	Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?. Metabolism: Clinical and Experimental, 2020, 108, 154260.	3.4	59
72	Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism: Clinical and Experimental, 2020, 109, 154282.	3.4	50

#	Article	IF	Citations
73	Association of circulating FGF-21 levels in the first week of life and postnatal growth in hospitalized preterm infants. Metabolism Open, 2020, 5, 100030.	2.9	2
74	Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism: Clinical and Experimental, 2020, 111, 154203.	3.4	88
75	Commentary: COVID-19 in patients with diabetes. Metabolism: Clinical and Experimental, 2020, 107, 154217.	3.4	136
76	New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. Metabolism: Clinical and Experimental, 2020, 107, 154218.	3.4	10
77	The effect of excess body fat on female and male reproduction. Metabolism: Clinical and Experimental, 2020, 107, 154193.	3.4	52
78	Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism. Bone, 2020, 138, 115510.	2.9	2
79	Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. Metabolism: Clinical and Experimental, 2020, 109, 154305.	3.4	10
80	Metabolic regulation of activins in healthy individuals and in obese patients undergoing bariatric surgery. Diabetes/Metabolism Research and Reviews, 2020, 36, e3297.	4.0	7
81	Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Metabolism: Clinical and Experimental, 2020, 104, 154144.	3.4	30
82	Sex specific effect of ATPase inhibitory factor 1 on body weight: studies in high fat diet induced obese mice and genetic association studies in humans. Metabolism: Clinical and Experimental, 2020, 105, 154171.	3.4	6
83	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Current Vascular Pharmacology, 2020, 18, 172-181.	1.7	54
84	Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next. Metabolism: Clinical and Experimental, 2020, 107, 154245.	3.4	67
85	The effect of underweight on female and male reproduction. Metabolism: Clinical and Experimental, 2020, 107, 154229.	3.4	69
86	Abnormal Peri-organ-Intra-organ Fat (APIFat) and Rheumatoid Arthritis: An Under-investigated Link for Increased Cardiovascular Risk?. Current Vascular Pharmacology, 2020, 18, 249-253.	1.7	4
87	Old and new tools to study human brain physiology: Current state, future directions and implications for metabolic regulation. Metabolism: Clinical and Experimental, 2019, 99, iii-viii.	3.4	11
88	Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?. Metabolism: Clinical and Experimental, 2019, 98, iii-ix.	3.4	24
89	Longerâ€term liraglutide administration at the highest dose approved for obesity increases rewardâ€related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to antiâ€obesity therapies. Diabetes, Obesity and Metabolism, 2019, 21, 2459-2464.	4.4	35
90	Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. Cardiovascular Diabetology, 2019, 18, 141.	6.8	30

#	Article	IF	Citations
91	Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials. Metabolism: Clinical and Experimental, 2019, 101, 153997.	3.4	62
92	Cord Leptin is Associated with Neuropsychomotor Development in Childhood. Obesity, 2019, 27, 1693-1702.	3.0	1
93	Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. Metabolism: Clinical and Experimental, 2019, 100, 153960.	3.4	16
94	Placental proteases PAPP-A and PAPP-A2, the binding proteins they cleave (IGFBP-4 and -5), and IGF-I and IGF-II: Levels in umbilical cord blood and associations with birth weight and length. Metabolism: Clinical and Experimental, 2019, 100, 153959.	3.4	17
95	Free Cortisol Is a More Accurate Marker for Adrenal Function and Does Not Correlate with Renal Function in Cirrhosis. Digestive Diseases and Sciences, 2019, 64, 1686-1694.	2.3	6
96	Fibroblast growth factor 21: A role in cardiometabolic disorders and cardiovascular risk prediction?. Metabolism: Clinical and Experimental, 2019, 93, iii-v.	3.4	7
97	Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. Metabolism: Clinical and Experimental, 2019, 93, 100-102.	3.4	11
98	Of mice and men: incretin actions in the central nervous system. Metabolism: Clinical and Experimental, 2019, 98, 121-135.	3.4	3
99	Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism: Clinical and Experimental, 2019, 96, 66-82.	3.4	72
100	Circulating levels of the components of the GH/IGF-1/IGFBPs axis total and intact IGF-binding proteins (IGFBP) 3 and IGFBP 4 and total IGFBP 5, as well as PAPPA, PAPPA2 and Stanniocalcin-2 levels are not altered in response to energy deprivation and/or metreleptin administration in humans. Metabolism: Clinical and Experimental, 2019, 97, 32-39.	3.4	8
101	Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. Metabolism: Clinical and Experimental, 2019, 96, iii-v.	3.4	16
102	Mechanisms underlying the cardiometabolic protective effect of walnut consumption in obese people: A crossâ€over, randomized, doubleâ€blind, controlled inpatient physiology study. Diabetes, Obesity and Metabolism, 2019, 21, 2086-2095.	4.4	33
103	Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. Metabolism: Clinical and Experimental, 2019, 96, 92-100.	3.4	40
104	Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. Metabolism: Clinical and Experimental, 2019, 96, vi-xi.	3.4	6
105	Beyond glycemic control: New guidance on cardio-renal protection. Metabolism: Clinical and Experimental, 2019, 99, 113-115.	3.4	5
106	Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A sixâ€month, randomized, placeboâ€controlled, doubleâ€blind clinical trial. Diabetes, Obesity and Metabolism, 2019, 21, 1487-1492.	4.4	38
107	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism: Clinical and Experimental, 2019, 101, 154005.	3.4	83
108	Serum Levels of Activins, Follistatins, and Growth Factors in Neoplasms of the Breast: A Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 349-358.	3.6	15

#	Article	IF	Citations
109	Follistatins in glucose regulation in healthy and obese individuals. Diabetes, Obesity and Metabolism, 2019, 21, 683-690.	4.4	36
110	Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice. Gastroenterology, 2019, 156, 203-217.e20.	1.3	50
111	Leptin trajectories from birth to mid-childhood and cardio-metabolic health in early adolescence. Metabolism: Clinical and Experimental, 2019, 91, 30-38.	3.4	26
112	Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism: Clinical and Experimental, 2019, 92, 121-135.	3.4	821
113	Could the endocrine disruptor bisphenol-A be implicated in the pathogenesis of oral and oropharyngeal cancer? Metabolic considerations and future directions. Metabolism: Clinical and Experimental, 2019, 91, 61-69.	3.4	25
114	Obesity: seize the day, fight the fat. Metabolism: Clinical and Experimental, 2019, 92, 1-5.	3.4	24
115	Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism: Clinical and Experimental, 2019, 92, 170-192.	3.4	184
116	Stem cells in the treatment of diabetes mellitus â€" Focus on mesenchymal stem cells. Metabolism: Clinical and Experimental, 2019, 90, 1-15.	3.4	88
117	Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls. Hormone and Metabolic Research, 2019, 51, 112-119.	1.5	7
118	Research developments in metabolism 2018. Metabolism: Clinical and Experimental, 2019, 91, 70-79.	3.4	2
119	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism: Clinical and Experimental, 2019, 92, 82-97.	3.4	679
120	GEOFFREY HARRIS PRIZE LECTURE 2018: Novel pathways regulating neuroendocrine function, energy homeostasis and metabolism in humans. European Journal of Endocrinology, 2019, 180, R59-R71.	3.7	14
121	Advances at the intersection of sleep and metabolism research. Metabolism: Clinical and Experimental, 2018, 84, 1-2.	3.4	4
122	Research advances in metabolism 2017. Metabolism: Clinical and Experimental, 2018, 83, 280-289.	3.4	0
123	Juvenile Paget disease. Metabolism: Clinical and Experimental, 2018, 80, 15-26.	3.4	32
124	The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges. Metabolism: Clinical and Experimental, 2018, 82, 72-87.	3.4	57
125	Sixty-six years of Metabolism, Clinical and Experimental: The journey of a journal and opportunities and challenges looking ahead. Metabolism: Clinical and Experimental, 2018, 78, A4-A9.	3.4	2
126	Inflammation: A key player linking obesity with malignancies. Metabolism: Clinical and Experimental, 2018, 81, A3-A6.	3.4	37

#	Article	IF	Citations
127	Reproductive Endocrinology: Novel Insights into Pathophysiology and Clinical Management. Metabolism: Clinical and Experimental, 2018, 86, 1-2.	3.4	2
128	Walnut consumption increases activation of the insula to highly desirable food cues: A randomized, doubleâ€blind, placeboâ€controlled, crossâ€over fMRI study. Diabetes, Obesity and Metabolism, 2018, 20, 173-177.	4.4	24
129	Bone metabolism in anorexia nervosa and hypothalamic amenorrhea. Metabolism: Clinical and Experimental, 2018, 80, 91-104.	3.4	15
130	Circulating ApoJ is closely associated with insulin resistance in human subjects. Metabolism: Clinical and Experimental, 2018, 78, 155-166.	3.4	24
131	Outliers of bone metabolic diseases. Metabolism: Clinical and Experimental, 2018, 80, 1-4.	3.4	4
132	Pharmacotherapy of type 2 diabetes: An update. Metabolism: Clinical and Experimental, 2018, 78, 13-42.	3.4	144
133	Obesity as a Disease. Medical Clinics of North America, 2018, 102, 13-33.	2.5	256
134	Irisin in metabolic diseases. Endocrine, 2018, 59, 260-274.	2.3	178
135	Antitumor and antimetastatic effects of walnut oil in esophageal adenocarcinoma cells. Clinical Nutrition, 2018, 37, 2166-2171.	5.0	25
136	Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: A cross sectional and a prospective case-control study nested in the Normative Aging Study. Metabolism: Clinical and Experimental, 2018, 79, 24-32.	3.4	57
137	Adipose tissue and reproductive health. Metabolism: Clinical and Experimental, 2018, 86, 18-32.	3.4	65
138	Physiology of Activins/Follistatins: Associations With Metabolic and Anthropometric Variables and Response to Exercise. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3890-3899.	3.6	31
139	Quantifying Platelet Margination in Diabetic BloodÂFlow. Biophysical Journal, 2018, 115, 1371-1382.	0.5	51
140	Non-alcoholic fatty liver disease and colorectal cancer: A marker of risk or common causation?. Metabolism: Clinical and Experimental, 2018, 87, A10-A13.	3.4	14
141	Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. Metabolism: Clinical and Experimental, 2018, 87, 18-24.	3.4	53
142	Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism, 2018, 33, 33.	3.0	120
143	Regulation of the activins-follistatins-inhibins axis by energy status: Impact on reproductive function. Metabolism: Clinical and Experimental, 2018, 85, 240-249.	3.4	32
144	Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies. Current Obesity Reports, 2018, 7, 260-275.	8.4	60

#	Article	IF	Citations
145	Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Thyroid, 2018, 28, 1270-1284.	4.5	87
146	Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics. Metabolism: Clinical and Experimental, 2018, 87, A1-A9.	3.4	83
147	Obese individuals with type 2 diabetes demonstrate decreased activation of the salienceâ€related insula and increased activation of the emotion/salienceâ€related amygdala to visual food cues compared to nonâ€obese individuals with diabetes: A preliminary study. Diabetes, Obesity and Metabolism, 2018, 20, 2500-2503.	4.4	6
148	Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook. Metabolism: Clinical and Experimental, 2017, 70, 192-195.	3.4	4
149	First and second trimester gestational weight gains are most strongly associated with cord blood levels of hormones at delivery important for glycemic control and somatic growth. Metabolism: Clinical and Experimental, 2017, 69, 112-119.	3.4	38
150	Treating prediabetes in the obese: are GLP-1 analogues the answer?. Lancet, The, 2017, 389, 1371-1372.	13.7	7
151	Physiology and role of irisin in glucose homeostasis. Nature Reviews Endocrinology, 2017, 13, 324-337.	9.6	403
152	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	3.4	208
153	Sleep apnea in relation to metabolism: An urgent need to study underlying mechanisms and to develop novel treatments for this unmet clinical need. Metabolism: Clinical and Experimental, 2017, 69, 207-210.	3.4	7
154	A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors. Cancer, 2017, 123, 2413-2421.	4.1	15
155	Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism: Clinical and Experimental, 2017, 73, 1-8.	3.4	53
156	Adiponectin, lipids and atherosclerosis. Current Opinion in Lipidology, 2017, 28, 347-354.	2.7	129
157	Associations of maternal prenatal smoking with umbilical cord blood hormones: the Project Viva cohort. Metabolism: Clinical and Experimental, 2017, 72, 18-26.	3.4	15
158	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism: Clinical and Experimental, 2017, 74, 43-46.	3.4	19
159	Effects of combined lowâ€dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, nonâ€invasive indices of steatosis and fibrosis, and adipokine levels in nonâ€alcoholic fatty liver disease: <scp>a</scp> randomized controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 1805-1809.	4.4	41
160	Lessons and Challenges from a 6-Month Randomized Pilot Study of Daily Ethanol Consumption. Current Developments in Nutrition, 2017, 1, e000505.	0.3	4
161	Cord Blood Adipocyte Fatty Acidâ€“Binding Protein Levels Correlate With Gestational Age and Birth Weight in Neonates. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1606-1613.	3.6	15
162	Associations of cord blood metabolites with perinatal characteristics, newborn anthropometry, and cord blood hormones in project viva. Metabolism: Clinical and Experimental, 2017, 76, 11-22.	3.4	43

#	Article	IF	Citations
163	Current child, but not maternal, snoring is bi-directionally related to adiposity and cardiometabolic risk markers: A cross-sectional and a prospective cohort analysis. Metabolism: Clinical and Experimental, 2017, 76, 70-80.	3.4	10
164	Physiological parameters regulating circulating levels of the IGFBP-4/Stanniocalcin-2/PAPP-A axis. Metabolism: Clinical and Experimental, 2017, 75, 16-24.	3.4	15
165	Lipodystrophy: Time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications. Metabolism: Clinical and Experimental, 2017, 72, A4-A10.	3.4	14
166	Research advances in metabolism 2016. Metabolism: Clinical and Experimental, 2017, 67, 41-53.	3.4	0
167	Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-Î³ agonists. Metabolism: Clinical and Experimental, 2017, 66, 64-68.	3.4	17
168	Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinology, 2017, 42, 92-108.	1.1	135
169	Decreasing Lean Body Mass with Age: Challenges and Opportunities for Novel Therapies. Endocrinology and Metabolism, 2017, 32, 422.	3.0	17
170	Obesity: Genetics, Pathogenesis, Therapy. , 2017, , 1-17.		1
171	Obesity: Genetics, Pathogenesis, and Therapy. , 2017, , 607-622.		0
172	Serum Adiponectin And Insulin-Like Growth Factor 1 In Predominantly Female Patients With Thyroid Cancer: Association With The Histologic Characteristics Of The Tumor. Endocrine Practice, 2016, 22, 68-75.	2.1	16
173	Novel Molecules Regulating Energy Homeostasis: Physiology and Regulation by Macronutrient Intake and Weight Loss. Endocrinology and Metabolism, 2016, 31, 361.	3.0	20
174	Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Diabetes, 2016, 65, 2943-2953.	0.6	49
175	Cord blood leptin levels in relation to child growth trajectories. Metabolism: Clinical and Experimental, 2016, 65, 874-882.	3.4	32
176	Differential Effects of Oral and Intravenous Lipid Administration on Key Molecules Related to Energy Homeostasis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1989-1997.	3.6	18
177	Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism: Clinical and Experimental, 2016, 65, 1109-1123.	3.4	363
178	Circulating follistatin displays a dayâ€“night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans. Metabolism: Clinical and Experimental, 2016, 65, 1459-1465.	3.4	19
179	Adiponectin administration prevents weight gain and glycemic profile changes in diet-induced obese immune deficient Rag1â^'/â^' mice lacking mature lymphocytes. Metabolism: Clinical and Experimental, 2016, 65, 1720-1730.	3.4	15
180	Statins in relation to adiponectin: A significant association with clinical implications. Atherosclerosis, 2016, 253, 270-272.	0.8	10

#	Article	IF	Citations
181	Sex-Specific Associations of Maternal Gestational Glycemia with Hormones in Umbilical Cord Blood at Delivery. American Journal of Perinatology, 2016, 33, 1273-1281.	1.4	24
182	Activin A and follistatin in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1550-1558.	3.4	27
183	Leptin and Hormones. Endocrinology and Metabolism Clinics of North America, 2016, 45, 633-645.	3.2	71
184	Circulating Chemerin Is Associated With Carotid Plaque Instability, Whereas Resistin Is Related to Cerebrovascular Symptomatology. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1670-1678.	2.4	35
185	Changes in Thyroid Hormone Levels Within the Normal and/or Subclinical Hyper- or Hypothyroid Range Do Not Affect Circulating Irisin Levels in Humans. Thyroid, 2016, 26, 1039-1045.	4.5	15
186	Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. Metabolism: Clinical and Experimental, 2016, 65, 1297-1306.	3.4	92
187	Immune therapy in type 1 diabetes mellitus â€" Attempts to untie the Gordian knot?. Metabolism: Clinical and Experimental, 2016, 65, 1278-1285.	3.4	8
188	Self-reported eating speed in relation to non-alcoholic fatty liver disease in adults. European Journal of Nutrition, 2016, 55, 327-333.	3.9	21
189	Hypovitaminosis D in bariatric surgery: A systematic review of observational studies. Metabolism: Clinical and Experimental, 2016, 65, 574-585.	3.4	107
190	Ciliary neurotrophic factor upregulates follistatin and Pak1, causes overexpression of muscle differentiation related genes and downregulation of established atrophy mediators in skeletal muscle. Metabolism: Clinical and Experimental, 2016, 65, 915-925.	3.4	16
191	Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study. Metabolism: Clinical and Experimental, 2016, 65, 945-953.	3.4	73
192	Central nervous system regulation of eating: Insights from human brain imaging. Metabolism: Clinical and Experimental, 2016, 65, 699-713.	3.4	132
193	Metabolic pathways link childhood adversity to elevated blood pressure in midlife adults. Obesity Research and Clinical Practice, 2016, 10, 580-588.	1.8	17
194	GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia, 2016, 59, 954-965.	6.3	176
195	Guidelines on vitamin D replacement in bariatric surgery: Identification and systematic appraisal. Metabolism: Clinical and Experimental, 2016, 65, 586-597.	3.4	50
196	Adipokines in nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1062-1079.	3.4	250
197	Nonalcoholic fatty future disease. Metabolism: Clinical and Experimental, 2016, 65, 1007-1016.	3.4	62
198	Research advances in metabolism 2015. Metabolism: Clinical and Experimental, 2016, 65, 27-37.	3.4	0

#	Article	IF	Citations
199	Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According toKRASMutation Status. Journal of the National Cancer Institute, 2016, 108, djv363.	6.3	37
200	Fetuin-A levels and free leptin index are reduced in patients with chronic lymphocytic leukemia: a hospital-based case-control study. Leukemia and Lymphoma, 2016, 57, 577-584.	1.3	7
201	Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia, 2016, 59, 30-43.	6.3	186
202	Lipodystrophy Syndromes. , 2016, , 648-661.e5.		4
203	Diet quality and diet patterns in relation to circulating cardiometabolic biomarkers. Clinical Nutrition, 2016, 35, 484-490.	5.0	47
204	Leptin applications in 2015. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 353-359.	2.3	170
205	Omentin-1 levels are reduced by pharmacologic doses of leptin, but remain unaffected by energy deprivation and display no dayâ€“night variation. International Journal of Obesity, 2015, 39, 260-264.	3.4	12
206	In prostate cancer, low adiponectin levels are not associated with insulin resistance. European Journal of Clinical Investigation, 2015, 45, 572-578.	3.4	11
207	Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: The Look AHEAD randomized trial. American Heart Journal, 2015, 170, 770-777.e5.	2.7	94
208	Irisin in Response to Exercise in Humans With and Without Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E453-E457.	3.6	150
209	Incretin Therapy and Beta Cell Function. Metabolism: Clinical and Experimental, 2015, 64, 157-159.	3.4	1
210	Impaired Autophagy Induces Chronic Atrophic Pancreatitis in Mice via Sex- and Nutrition-Dependent Processes. Gastroenterology, 2015, 148, 626-638.e17.	1.3	130
211	Cohort Profile: Project Viva. International Journal of Epidemiology, 2015, 44, 37-48.	1.9	275
212	New-Onset Diabetes and Statins: Throw the Bath Water Out, But, Please, Keep the Baby!. Metabolism: Clinical and Experimental, 2015, 64, 471-475.	3.4	25
213	Cord blood irisin levels are positively correlated with birth weight in newborn infants. Metabolism: Clinical and Experimental, 2015, 64, 1507-1514.	3.4	31
214	From rest to stressed: endothelin-1 levels in young healthy smokers and non-smokers. Metabolism: Clinical and Experimental, 2015, 64, 1103-1111.	3.4	8
215	An update on the validity of irisin assays and the link between irisin and hepatic metabolism. Metabolism: Clinical and Experimental, 2015, 64, 937-942.	3.4	50
216	Slip sliding away: the need for continued discussion of the use of insulin sliding scale in hospitalized patients. Metabolism: Clinical and Experimental, 2015, 64, 935-936.	3.4	3

#	Article	IF	Citations
217	Intracellular leptin signaling following effective weight loss. Metabolism: Clinical and Experimental, 2015, 64, 888-895.	3.4	8
218	Leptin Therapy in Women with Hypothalamic Amenorrhea. , 2015, , 237-254.		0
219	Identification and Saturable Nature of Signaling Pathways Induced by Metreleptin in Humans: Comparative Evaluation of In Vivo, Ex Vivo, and In Vitro Administration. Diabetes, 2015, 64, 828-839.	0.6	18
220	Irisin physiology, oxidative stress, and thyroid dysfunction: What next?. Metabolism: Clinical and Experimental, 2015, 64, 765-767.	3.4	24
221	Dietary walnut suppression of colorectal cancer in mice: Mediation by miRNA patterns and fatty acid incorporation. Journal of Nutritional Biochemistry, 2015, 26, 776-783.	4.2	74
222	Irisin: A true, circulating hormone. Metabolism: Clinical and Experimental, 2015, 64, 1611-1618.	3.4	48
223	Undiagnosed diabetes is prevalent in younger adults and associated with a higher risk cardiometabolic profile compared to diagnosed diabetes. American Heart Journal, 2015, 170, 760-769.e2.	2.7	24
224	Early life adversity and/or posttraumatic stress disorder severity are associated with poor diet quality, including consumption of trans fatty acids, and fewer hours of resting or sleeping in a US middle-aged population: A cross-sectional and prospective study. Metabolism: Clinical and Experimental, 2015, 64, 1597-1610.	3.4	35
225	Leptin in Health and Disease: Facts and Expectations at its Twentieth Anniversary. Metabolism: Clinical and Experimental, 2015, 64, 5-12.	3.4	49
226	The role of leptin in regulating bone metabolism. Metabolism: Clinical and Experimental, 2015, 64, 105-113.	3.4	193
227	Leptin in autoimmune diseases. Metabolism: Clinical and Experimental, 2015, 64, 92-104.	3.4	85
228	From leptin to other adipokines in health and disease: Facts and expectations at the beginning of the 21st century. Metabolism: Clinical and Experimental, 2015, 64, 131-145.	3.4	332
229	Leptin in nonalcoholic fatty liver disease: A narrative review. Metabolism: Clinical and Experimental, 2015, 64, 60-78.	3.4	170
230	Leptin in congenital and HIV-associated lipodystrophy. Metabolism: Clinical and Experimental, 2015, 64, 47-59.	3.4	50
231	Leptin: A hormone linking activation of neuroendocrine axes with neuropathology. Psychoneuroendocrinology, 2015, 51, 47-57.	2.7	63
232	Leptin and the brain: Influences on brain development, cognitive functioning and psychiatric disorders. Metabolism: Clinical and Experimental, 2015, 64, 114-130.	3.4	112
233	Obesity: Genetics, Pathogenesis, Therapy. , 2015, , 1-17.		1
234	Circulating Irisin Levels Are Not Affected by Coffee Intake: A Randomized Controlled Trial. PLoS ONE, 2014, 9, e94463.	2.5	7

#	Article	IF	Citations
235	Can a Selective PPARÎ³ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?. Diabetes Care, 2014, 37, 1918-1923.	8.6	61
236	Circulating fetuin-A in patients with pancreatic cancer: a hospital-based case-control study. Biomarkers, 2014, 19, 660-666.	1.9	10
237	Leptin Therapy Alters Appetite and Neural Responses to Food Stimuli in Brain Areas of Leptin-Sensitive Subjects Without Altering Brain Structure. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2529-E2538.	3.6	36
238	The Effect of Leptin Replacement on Parathyroid Hormone, RANKL-Osteoprotegerin Axis, and Wnt Inhibitors in Young Women With Hypothalamic Amenorrhea. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2252-E2258.	3.6	25
239	Alpha linolenic acid and oleic acid additively down-regulate malignant potential and positively cross-regulate AMPK/S6 axis in OE19 and OE33 esophageal cancer cells. Metabolism: Clinical and Experimental, 2014, 63, 1447-1454.	3.4	48
240	Cord blood levels of osteopontin as a phenotype marker of gestational age and neonatal morbidities. Obesity, 2014, 22, 1317-1324.	3.0	9
241	20 YEARS OF LEPTIN: Role of leptin in human reproductive disorders. Journal of Endocrinology, 2014, 223, T49-T62.	2.6	78
242	Irisin in response to acute and chronic whole-body vibration exercise in humans. Metabolism: Clinical and Experimental, 2014, 63, 918-921.	3.4	86
243	Effects of a 1â€year exercise and lifestyle intervention on irisin, adipokines, and inflammatory markers in obese children. Obesity, 2014, 22, 1701-1708.	3.0	106
244	Irisin in humans: recent advances and questions for future research. Metabolism: Clinical and Experimental, 2014, 63, 178-180.	3.4	66
245	Irisin in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2014, 63, 207-217.	3.4	179
246	Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2014, 63, 161-167.	3.4	69
247	Implication of Circulating Irisin Levels with Brown Adipose Tissue and Sarcopenia in Humans. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2778-2785.	3.6	64
248	Plasma irisin levels progressively increase in response to increasing exercise workloads in young, healthy, active subjects. European Journal of Endocrinology, 2014, 171, 343-352.	3.7	155
249	Exercise-Induced Irisin Secretion Is Independent of Age or Fitness Level and Increased Irisin May Directly Modulate Muscle Metabolism Through AMPK Activation. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2154-E2161.	3.6	263
250	A prospective study of maternal prenatal weight and offspring cardiometabolic health in midchildhood. Annals of Epidemiology, 2014, 24, 793-800.e1.	1.9	100
251	Circulating Irisin in Healthy, Young Individuals: Day-Night Rhythm, Effects of Food Intake and Exercise, and Associations With Gender, Physical Activity, Diet, and Body Composition. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3247-3255.	3.6	133
252	Early Life Adversity Is Associated With Elevated Levels of Circulating Leptin, Irisin, and Decreased Levels of Adiponectin in Midlife Adults. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1055-E1060.	3.6	54

#	Article	IF	Citations
253	Statin treatment and new-onset diabetes: A review of proposed mechanisms. Metabolism: Clinical and Experimental, 2014, 63, 735-745.	3.4	186
254	Relations of Plasma Total and High-Molecular-Weight Adiponectin to New-Onset Heart Failure in Adults â‰¥65 Years of Age (from the Cardiovascular Health Study). American Journal of Cardiology, 2014, 113, 328-334.	1.6	39
255	Circulating alanine transaminase (ALT) and Î³-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: The prospective Cyprus Metabolism Study. Metabolism: Clinical and Experimental, 2014, 63, 773-782.	3.4	36
256	Chemerin levels as predictor of acute coronary events: A caseâ€“control study nested within the veterans affairs normative aging study. Metabolism: Clinical and Experimental, 2014, 63, 760-766.	3.4	21
257	Circulating fetuin-A levels are not affected by short and long-term energy deprivation and/or by leptin administration. Metabolism: Clinical and Experimental, 2014, 63, 754-759.	3.4	10
258	Detailed assessments of childhood adversity enhance prediction of central obesity independent of gender, race, adult psychosocial risk and health behaviors. Metabolism: Clinical and Experimental, 2014, 63, 199-206.	3.4	55
259	Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism: Clinical and Experimental, 2014, 63, 1265-1271.	3.4	90
260	Potential cardioprotective action of GLP-1: from bench to bedside. Metabolism: Clinical and Experimental, 2014, 63, 979-988.	3.4	11
261	Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: A randomized controlled cross-over clinical trial. Metabolism: Clinical and Experimental, 2014, 63, 382-391.	3.4	75
262	Diet quality is associated with circulating C-reactive protein but not irisin levels in humans. Metabolism: Clinical and Experimental, 2014, 63, 233-241.	3.4	70
263	Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines. Metabolism: Clinical and Experimental, 2014, 63, 188-193.	3.4	71
264	Diet patterns, adipokines, and metabolism: Where are we and what is next?. Metabolism: Clinical and Experimental, 2014, 63, 168-177.	3.4	22
265	Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism: Clinical and Experimental, 2013, 62, 1131-1136.	3.4	149
266	Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. European Journal of Endocrinology, 2013, 169, 829-834.	3.7	55
267	Advances in metabolism. Metabolism: Clinical and Experimental, 2013, 62, 1700-1713.	3.4	11
268	Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome. Metabolism: Clinical and Experimental, 2013, 62, 1830-1839.	3.4	41
269	Circulating Irisin in Relation to Insulin Resistance and the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4899-4907.	3.6	409
270	Differential associations of leptin with adiposity across early childhood. Obesity, 2013, 21, 1430-1437.	3.0	68

#	Article	IF	Citations
271	Gender and body mass index modify the effect of increasing amounts of caffeinated coffee on postprandial glucose and insulin concentrations; a randomized, controlled, clinical trial. Metabolism: Clinical and Experimental, 2013, 62, 1099-1106.	3.4	27
272	Adipokines in the HIV/HAART-associated lipodystrophy syndrome. Metabolism: Clinical and Experimental, 2013, 62, 1199-1205.	3.4	37
273	Irisin: A renaissance in metabolism?. Metabolism: Clinical and Experimental, 2013, 62, 1037-1044.	3.4	113
274	Leptin at the Intersection of Neuroendocrinology and Metabolism: Current Evidence and Therapeutic Perspectives. Cell Metabolism, 2013, 18, 29-42.	16.2	178
275	Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut, 2013, 62, 561-570.	12.1	91
276	Chemerin is expressed mainly in pancreas and liver, is regulated by energy deprivation, and lacks day/night variation in humans. European Journal of Endocrinology, 2013, 169, 453-462.	3.7	33
277	Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals. Endocrine Reviews, 2013, 34, 377-412.	20.1	212
278	Fibroblast Growth Factor 21 Levels in Young Healthy Females Display Day and Night Variations and Are Increased in Response to Short-Term Energy Deprivation Through a Leptin-Independent Pathway. Diabetes Care, 2013, 36, 935-942.	8.6	18
279	Gender Dimorphism and Lack of Day/Night Variation or Effects of Energy Deprivation on Undercarboxylated Osteocalcin Levels in Humans. Obesity, 2013, 21, E527-32.	3.0	1
280	Selective capacity of metreleptin administration to reconstitute CD4 ⁺ T-cell number in females with acquired hypoleptinemia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E818-27.	7.1	41
281	Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo. PLoS ONE, 2013, 8, e72858.	2.5	104
282	Responses of circulating irisin to different exercises in humans. FASEB Journal, 2013, 27, 712.17.	0.5	0
283	Selective PPARÎ³ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E552-E560.	3.5	39
284	Secretion Patterns of Circulating Osteoprotegerin and Response to Acute and Chronic Energy Deprivation in Young Healthy Adults. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2765-2772.	3.6	1
285	Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: A need for more mechanistic studies and large, randomized, placebo-controlled trials. Metabolism: Clinical and Experimental, 2012, 61, 1331-1336.	3.4	16
286	The Role of Adiponectin in Cancer: A Review of Current Evidence. Endocrine Reviews, 2012, 33, 547-594.	20.1	532
287	Advances in adipokines. Metabolism: Clinical and Experimental, 2012, 61, 1659-1665.	3.4	60
288	FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism: Clinical and Experimental, 2012, 61, 1725-1738.	3.4	812

#	Article	IF	Citations
289	Leptin as a Modulator of Neuroendocrine Function in Humans. Yonsei Medical Journal, 2012, 53, 671.	2.2	54
290	Leptin in Relation to the Lipodystrophy-Associated Metabolic Syndrome. Diabetes and Metabolism Journal, 2012, 36, 181.	4.7	22
291	Short-term walnut consumption increases circulating total adiponectin and apolipoprotein A concentrations, but does not affect markers of inflammation or vascular injury in obese humans with the metabolic syndrome: data from a double-blinded, randomized, placebo-controlled study. Metabolism: Clinical and Experimental, 2012, 61, 577-582.	3.4	49
292	Optimizing bone health in anorexia nervosa and hypothalamic amenorrhea: new trials and tribulations. Metabolism: Clinical and Experimental, 2012, 61, 899-905.	3.4	13
293	Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. European Journal of Endocrinology, 2011, 165, 249-254.	3.7	51
294	Serum adipocyte fatty acidâ€“binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. American Journal of Clinical Nutrition, 2011, 93, 19-26.	4.7	48
295	Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: the Cyprus Metabolism Prospective Cohort Study. Metabolism: Clinical and Experimental, 2011, 60, 987-993.	3.4	41
296	Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment. Metabolism: Clinical and Experimental, 2011, 60, 749-753.	3.4	38
297	Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virusâ€“infected lipoatrophic men treated with pioglitazone: a pilot study. Metabolism: Clinical and Experimental, 2011, 60, 1045-1049.	3.4	39
298	Insulin resistance: an independent risk factor for lung cancer?. Metabolism: Clinical and Experimental, 2011, 60, 1100-1106.	3.4	57
299	Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations. Metabolism: Clinical and Experimental, 2011, 60, 1294-1299.	3.4	30
300	Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism: Clinical and Experimental, 2011, 60, 1530-1538.	3.4	70
301	Serum adiponectin and leptin in relation to risk for preeclampsia: results from a large case-control study. Metabolism: Clinical and Experimental, 2011, 60, 1539-1544.	3.4	38
302	Effects of leptin and adiponectin on pancreatic Î²-cell function. Metabolism: Clinical and Experimental, 2011, 60, 1664-1672.	3.4	120
303	Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism: Clinical and Experimental, 2011, 60, 1211-1221.	3.4	145
304	Gestational Glucose Tolerance and Cord Blood Leptin Levels Predict Slower Weight Gain in Early Infancy. Journal of Pediatrics, 2011, 158, 227-233.	1.8	47
305	Lipodystrophy: pathophysiology and advances in treatment. Nature Reviews Endocrinology, 2011, 7, 137-150.	9.6	208
306	The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. BMC Medical Genetics, 2011, 12, 52.	2.1	132

#	Article	IF	Citations
307	Preadipocyte Factor-1 Levels Are Higher in Women with Hypothalamic Amenorrhea and Are Associated with Bone Mineral Content and Bone Mineral Density through a Mechanism Independent of Leptin. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1634-E1639.	3.6	24
308	Circulating Adiponectin Is Inversely Associated with Risk of Thyroid Cancer:In Vivoandin VitroStudies. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E2023-E2028.	3.6	61
309	Energy Deprivation Alters in a Leptin- and Cortisol-Independent Manner Circulating Levels of Activin A and Follistatin But Not Myostatin in Healthy Males. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3416-3423.	3.6	42
310	Short-Term Energy Deprivation Alters Activin A and Follistatin But Not Inhibin B Levels of Lean Healthy Women in a Leptin-Independent Manner. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3750-3758.	3.6	15
311	Brain responses to food images during the early and late follicular phase of the menstrual cycle in healthy young women: relation to fasting and feeding. American Journal of Clinical Nutrition, 2011, 94, 377-384.	4.7	53
312	Insulin resistance in relation to melanoma risk. Melanoma Research, 2011, 21, 541-546.	1.2	30
313	Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency or leptin administration in humans. European Journal of Endocrinology, 2011, 164, 911-917.	3.7	18
314	Direct Role of Adiponectin and Adiponectin Receptors in Endometrial Cancer: In Vitro and Ex Vivo Studies in Humans. Molecular Cancer Therapeutics, 2011, 10, 2234-2243.	4.1	69
315	Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular and Molecular Pathways Underlying Leptin Tolerance. Diabetes, 2011, 60, 1647-1656.	0.6	129
316	Leptin and Amylin Act in an Additive Manner to Activate Overlapping Signaling Pathways in Peripheral Tissues. Diabetes Care, 2011, 34, 132-138.	8.6	132
317	Leptin in human physiology and pathophysiology. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E567-E584.	3.5	458
318	Leptin is an effective treatment for hypothalamic amenorrhea. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6585-6590.	7.1	245
319	Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E99-E104.	3.5	23
320	Leptin administered in physiologic or pharmacologic doses does not regulate circulating angiogenesis factors in humans. FASEB Journal, 2011, 25, 1091.7.	0.5	0
321	W(h)ither Metreleptin for Lipodystrophy and the Metabolic Syndrome?. Endocrine Practice, 2010, 16, 162-166.	2.1	10
322	Adiponectin Receptor Expression in Human Malignant Tissues. Hormones and Cancer, 2010, 1, 136-145.	4.9	27
323	B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a caseâ€“control study in Greece. Cancer Causes and Control, 2010, 21, 1451-1459.	1.8	35
324	Accepting the torch. Metabolism: Clinical and Experimental, 2010, 59, 1394-1395.	3.4	2

#	Article	IF	Citations
325	Maternal diet and cord blood leptin and adiponectin concentrations at birth. Clinical Nutrition, 2010, 29, 622-626.	5.0	24
326	Leptin in human physiology and therapeutics. Frontiers in Neuroendocrinology, 2010, 31, 377-393.	5.2	223
327	Walnut Consumption Increases Satiation but Has No Effect on Insulin Resistance or the Metabolic Profile Over a 4â€day Period. Obesity, 2010, 18, 1176-1182.	3.0	84
328	Adiponectin in insulin resistance: lessons from translational research. American Journal of Clinical Nutrition, 2010, 91, 258S-261S.	4.7	324
329	Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. European Journal of Endocrinology, 2010, 162, 281-288.	3.7	79
330	Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels. Human Molecular Genetics, 2010, 19, 1846-1855.	2.9	74
331	Leptin and Soluble Leptin Receptor Levels in Plasma and Risk of Type 2 Diabetes in U.S. Women. Diabetes, 2010, 59, 611-618.	0.6	93
332	Narrative Review: The Role of Leptin in Human Physiology: Emerging Clinical Applications. Annals of Internal Medicine, 2010, 152, 93.	3.9	499
333	Obesity â€“ Genetics, Pathogenesis, Therapy. , 2010, , 475-488.		0
334	Lipodystrophy Syndromes. , 2010, , 722-734.		2
335	Serum Adiponectin As a Predictor of Childhood Non-Hodgkin's Lymphoma: A Nationwide Case-Control Study. Journal of Clinical Oncology, 2009, 27, 5049-5055.	1.6	34
336	Leptin in humans: lessons from translational research. American Journal of Clinical Nutrition, 2009, 89, 991S-997S.	4.7	156
337	r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. European Journal of Endocrinology, 2009, 160, 173-176.	3.7	37
338	Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome?. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1089-1091.	3.6	21
339	Phobic Anxiety Is Associated With Higher Serum Concentrations of Adipokines and Cytokines in Women With Diabetes. Diabetes Care, 2009, 32, 926-931.	8.6	53
340	Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a caseâ€“control study. Cancer Causes and Control, 2009, 20, 193-199.	1.8	89
341	Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a caseâ€“control study. Cancer Causes and Control, 2009, 20, 625-633.	1.8	105
342	Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study. Pediatrics, 2009, 123, 682-689.	2.1	215

#	Article	IF	Citations
343	Mediterranean Diet and Incidence of and Mortality From Coronary Heart Disease and Stroke in Women. Circulation, 2009, 119, 1093-1100.	1.6	688
344	Adverse metabolic and cardiovascular consequences of circadian misalignment. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4453-4458.	7.1	1,770
345	Leptin Deficiency: Clinical Implications and Opportunities for Therapeutic Interventions. Journal of Investigative Medicine, 2009, 57, 784-788.	1.6	45
346	Environmental Inputs, Intake of Nutrients, and Endogenous Molecules Contributing to the Regulation of Energy Homeostasis. , 2009, , 41-75.		1
347	Insulin Resistance in States of Energy Excess: Underlying Pathophysiological Concepts. , 2009, , 107-122.		1
348	Mediterranean diet and incidence and mortality of coronary heart disease and stroke in women. FASEB Journal, 2009, 23, 214.3.	0.5	0
349	Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clinical Endocrinology, 2008, 68, 536-541.	2.4	44
350	A dietary pattern characterized by high consumption of whole-grain cereals and low-fat dairy products and low consumption of refined cereals is positively associated with plasma adiponectin levels in healthy women. Metabolism: Clinical and Experimental, 2008, 57, 824-830.	3.4	65
351	Pharmacokinetics of Subcutaneous Recombinant Methionyl Human Leptin Administration in Healthy Subjects in the Fed and Fasting States. Clinical Pharmacokinetics, 2008, 47, 753-764.	3.5	40
352	Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. European Journal of Cancer, 2008, 44, 1744-1753.	2.8	41
353	Dietary Patterns and Risk of Mortality From Cardiovascular Disease, Cancer, and All Causes in a Prospective Cohort of Women. Circulation, 2008, 118, 230-237.	1.6	438
354	Leptin Does Not Directly Regulate the Pancreatic Hormones Amylin and Pancreatic Polypeptide: Interventional studies in humans. Diabetes Care, 2008, 31, 945-951.	8.6	19
355	Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocrine-Related Cancer, 2008, 15, 289-299.	3.1	73
356	Leptin Does Not Mediate Short-Term Fasting-Induced Changes in Growth Hormone Pulsatility but Increases IGF-I in Leptin Deficiency States. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2819-2827.	3.6	65
357	Dietary factors associated with plasma high molecular weight and total adiponectin levels in apparently healthy women. European Journal of Endocrinology, 2008, 159, R5-R10.	3.7	16
358	Coffee Consumption Is Associated With Higher Plasma Adiponectin Concentrations in Women With or Without Type 2 Diabetes. Diabetes Care, 2008, 31, 504-507.	8.6	138
359	Variants of the Adiponectin and Adiponectin Receptor 1 Genes and Breast Cancer Risk. Cancer Research, 2008, 68, 3178-3184.	0.9	104
360	Total and High-Molecular-Weight Adiponectin and Resistin in Relation to the Risk for Type 2 Diabetes in Women. Annals of Internal Medicine, 2008, 149, 307.	3.9	180

#	Article	IF	Citations
361	The Development of INT131 as a Selective PPAR Modulator: Approach to a Safer Insulin Sensitizer. PPAR Research, 2008, 2008, 1-9.	2.4	66
362	Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study. American Journal of Clinical Nutrition, 2008, 88, 1213-24.	4.7	101
363	Gene Expression of Adiponectin Receptors in Human Visceral and Subcutaneous Adipose Tissue Is Related to Insulin Resistance and Metabolic Parameters and Is Altered in Response to Physical Training. Diabetes Care, 2007, 30, 3110-3115.	8.6	89
364	High Circulating Leptin Receptors with Normal Leptin Sensitivity in Liver-specific Insulin Receptor Knock-out (LIRKO) Mice. Journal of Biological Chemistry, 2007, 282, 23672-23678.	3.4	56
365	Leptin and Adipocytokines: Bridging the Gap Between Immunity and Atherosclerosis. Current Pharmaceutical Design, 2007, 13, 3676-3680.	1.9	61
366	Circulating Adiponectin Levels and Expression of Adiponectin Receptors in Relation to Lung Cancer: Two Case-Control Studies. Oncology, 2007, 73, 261-269.	1.9	73
367	Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1079-E1086.	3.5	127
368	Serum Adiponectin Concentrations and Tissue Expression of Adiponectin Receptors Are Reduced in Patients with Prostate Cancer: A Case Control Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 308-313.	2.5	160
369	The role of adipokines in relation to HIV lipodystrophy. Aids, 2007, 21, 895-904.	2.2	45
370	Circulating Adiponectin and Leptin in Relation to Myelodysplastic Syndrome: A Case-Control Study. Oncology, 2007, 73, 26-32.	1.9	45
371	Pharmacokinetics of Recombinant Methionyl Human Leptin after Subcutaneous Administration: Variation of Concentration-Dependent Parameters According to Assay. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2307-2311.	3.6	31
372	Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer. European Journal of Endocrinology, 2007, 156, 187-194.	3.7	15
373	Sleep Duration and Snoring in Relation to Biomarkers of Cardiovascular Disease Risk Among Women With Type 2 Diabetes. Diabetes Care, 2007, 30, 1233-1240.	8.6	139
374	Leptin in reproduction. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 458-464.	2.3	130
375	Breast-feeding, Adipokines, and Childhood Obesity. Epidemiology, 2007, 18, 730-732.	2.7	21
376	Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. Atherosclerosis, 2007, 191, 121-127.	0.8	38
377	Diabetes and Risk of Endometrial Cancer: A Population-Based Prospective Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 276-280.	2.5	143
378	Total and High-Molecular-Weight Adiponectin in Breast Cancer:In Vitroandin VivoStudies. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1041-1048.	3.6	207

#	Article	IF	Citations
379	Plasma Adiponectin Concentrations and Risk of Incident Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1510-1516.	3.6	248
380	Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. American Journal of Clinical Nutrition, 2007, 86, 858S-866S.	4.7	300
381	Low adiponectin levels are associated with renal cell carcinoma: A caseâ€control study. International Journal of Cancer, 2007, 120, 1573-1578.	5.1	117
382	Leptin and adiponectin: Their role in diabetes. Current Diabetes Reports, 2007, 7, 1-2.	4.2	29
383	Drug Insight: the role of leptin in human physiology and pathophysiologyâ€"emerging clinical applications. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 318-327.	2.8	310
384	Adiponectin: a link between obesity and cancer. Expert Opinion on Investigational Drugs, 2006, 15, 917-931.	4.1	104
385	Leptin and Its Emerging Role in Children and Adolescents. Clinical Pediatric Endocrinology, 2006, 15, 1-14.	0.8	7
386	Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. American Journal of Clinical Nutrition, 2006, 84, 328-335.	4.7	156
387	Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women1â€"3. American Journal of Clinical Nutrition, 2006, 84, 328-335.	4.7	176
388	Short-term fasting-induced autonomic activation and changes in catecholamine levels are not mediated by changes in leptin levels in healthy humans. Clinical Endocrinology, 2006, 66, 061011075413002-???.	2.4	49
389	Recombinant Methionyl Human Leptin Therapy in Replacement Doses Improves Insulin Resistance and Metabolic Profile in Patients with Lipoatrophy and Metabolic Syndrome Induced by the Highly Active Antiretroviral Therapy. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2605-2611.	3.6	159
390	Leptin Receptor Expression and Signaling in Lymphocytes: Kinetics During Lymphocyte Activation, Role in Lymphocyte Survival, and Response to High Fat Diet in Mice. Journal of Immunology, 2006, 176, 7745-7752.	0.8	207
391	Adiponectin Genetic Variability, Plasma Adiponectin, and Cardiovascular Risk in Patients With Type 2 Diabetes. Diabetes, 2006, 55, 1512-1516.	0.6	119
392	Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8481-8486.	7.1	188
393	Dietary Fibers and Glycemic Load, Obesity, and Plasma Adiponectin Levels in Women With Type 2 Diabetes. Diabetes Care, 2006, 29, 1501-1505.	8.6	102
394	Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications. American Journal of Infectious Diseases, 2006, 2, 141-152.	0.2	39
395	Insulin Resistance, Obesity, Body Fat Distribution, and Risk of Cardiovascular Disease. Fundamental and Clinical Cardiology, 2006, , 51-74.	0.0	0
396	Nutrients and Peripherally Secreted Molecules in Regulation of Energy Homeostasis. , 2006, , 69-86.		1

#	Article	IF	Citations
397	The emerging role of leptin in humans. Pediatric Endocrinology Reviews, 2006, 3, 239-48.	1.2	32
398	Neonatal leptin levels are strongly associated with female gender, birth length, IGFâ€‰levels and formula feeding. Clinical Endocrinology, 2005, 62, 366-371.	2.4	55
399	Authorsâ€™ Response: Leptin Therapy Does Not Affect Inflammatory Markers. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3803-3803.	3.6	1
400	Circulating Melanin-Concentrating Hormone, Agouti-Related Protein, and Î±-Melanocyte-Stimulating Hormone Levels in Relation to Body Composition: Alterations in Response to Food Deprivation and Recombinant Human Leptin Administration. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1047-1054.	3.6	66
401	Independent Circadian and Sleep/Wake Regulation of Adipokines and Glucose in Humans. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2537-2544.	3.6	211
402	Recombinant Methionyl Human Leptin Administration Activates Signal Transducer and Activator of Transcription 3 Signaling in Peripheral Blood Mononuclear Cellsin Vivoand Regulates Soluble Tumor Necrosis Factor-Î± Receptor Levels in Humans with Relative Leptin Deficiency. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1625-1631.	3.6	63
403	Circulating Adiponectin Levels Are Associated with Better Glycemic Control, More Favorable Lipid Profile, and Reduced Inflammation in Women with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4542-4548.	3.6	193
404	Leptin in Immunology. Journal of Immunology, 2005, 174, 3137-3142.	0.8	500
405	Improvement in Highly Active Antiretroviral Therapy–Induced Metabolic Syndrome by Treatment with Pioglitazone but Not with Fenofibrate: A 2 x 2 Factorial, Randomized, Double-Blinded, Placebo-Controlled Trial. Clinical Infectious Diseases, 2005, 40, 745-749.	5.8	56
406	Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet, The, 2005, 366, 74-85.	13.7	324
407	Low Plasma Adiponectin Levels and Risk of Colorectal Cancer in Men: A Prospective Study. Journal of the National Cancer Institute, 2005, 97, 1688-1694.	6.3	449
408	Recombinant Methionyl Human Leptin Administration to Achieve High Physiologic or Pharmacologic Leptin Levels Does Not Alter Circulating Inflammatory Marker Levels in Humans with Leptin Sufficiency or Excess. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1618-1624.	3.6	66
409	The Role of Leptin in Regulating Neuroendocrine Function in Humans. Journal of Nutrition, 2004, 134, 2469S-2474S.	2.9	57
410	Leptin Hormonal Kinetics in the Fed State: Effects of Adiposity, Age, and Gender on Endogenous Leptin Production and Clearance Rates. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2672-2677.	3.6	53
411	Ghrelin Levels Are Not Regulated by Recombinant Leptin Administration and/or Three Days of Fasting in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 335-343.	3.6	126
412	Recombinant Human Leptin in Women with Hypothalamic Amenorrhea. New England Journal of Medicine, 2004, 351, 987-997.	27.0	821
413	Serum adiponectin concentrations in relation to maternaland perinatal characteristics in newborns. European Journal of Endocrinology, 2004, 151, 741-746.	3.7	45
414	Ciliary Neurotrophic FactorAx15 Alters Energy Homeostasis, Decreases Body Weight, and Improves Metabolic Control in Diet-Induced Obese and UCP1-DTA Mice. Diabetes, 2004, 53, 2787-2796.	0.6	64

#	Article	IF	Citations
415	Elevated leptin fragments in renal failure correlate with BMI and haematopoiesis and are normalized by haemodialysis. Clinical Endocrinology, 2004, 60, 434-441.	2.4	15
416	Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clinical Endocrinology, 2004, 61, 332-338.	2.4	132
417	Adiponectin and Breast Cancer Risk. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1102-1107.	3.6	488
418	Circulating Adiponectin and Resistin Levels in Relation to Metabolic Factors, Inflammatory Markers, and Vascular Reactivity in Diabetic Patients and Subjects at Risk for Diabetes. Diabetes Care, 2004, 27, 2450-2457.	8.6	374
419	Circulating Adiponectin and Endometrial Cancer Risk. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1160-1163.	3.6	247
420	Energy Homeostasis, Obesity and Eating Disorders: Recent Advances in Endocrinology. Journal of Nutrition, 2004, 134, 295-298.	2.9	214
421	Obesity â€" Genetics, Pathogenesis, Therapy. , 2004, , 655-669.		0
422	Effect of Lifestyle Modification on Adipokine Levels in Obese Subjects with Insulin Resistance. Obesity, 2003, 11, 1048-1054.	4.0	326
423	Plasma Adiponectin Concentrations in Relation to Endometrial Cancer: A Case-Control Study in Greece. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 993-997.	3.6	219
424	Body Fat Mass and Macronutrient Intake in Relation to Circulating Soluble Leptin Receptor, Free Leptin Index, Adiponectin, and Resistin Concentrations in Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1730-1736.	3.6	374
425	Circulating Resistin Levels Are Not Associated with Obesity or Insulin Resistance in Humans and Are Not Regulated by Fasting or Leptin Administration: Cross-Sectional and Interventional Studies in Normal, Insulin-Resistant, and Diabetic Subjects. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4848-4856.	3.6	500
426	Hypoadiponectinemia Is Associated with Insulin Resistance, Hypertriglyceridemia, and Fat Redistribution in Human Immunodeficiency Virus-Infected Patients Treated with Highly Active Antiretroviral Therapy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 627-636.	3.6	207
427	Diurnal and Ultradian Dynamics of Serum Adiponectin in Healthy Men: Comparison with Leptin, Circulating Soluble Leptin Receptor, and Cortisol Patterns. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2838-2843.	3.6	299
428	Human Immunodeficiency Virus Type 1â€"Related Lipoatrophy and Lipohypertrophy Are Associated with Serum Concentrations of Leptin. Clinical Infectious Diseases, 2003, 36, 795-802.	5.8	102
429	Relationship of Leptin to Bone Mineralization in Children and Adolescents. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 599-604.	3.6	66
430	Serum Adiponectin Levels Are Inversely Associated with Overall and Central Fat Distribution but Are Not Directly Regulated by Acute Fasting or Leptin Administration in Humans: Cross-Sectional and Interventional Studies. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4823-4831.	3.6	396
431	Leptin and Pubertal Development in Humans. , 2003, , 151-167.		1
432	Leptin and Fetal Growth and Development. , 2003, , 189-200.		1

#	Article	IF	Citations
433	The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. Journal of Clinical Investigation, 2003, 111, 1409-1421.	8.2	266
434	The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. Journal of Clinical Investigation, 2003, 111, 1409-1421.	8.2	468
435	Regulation of Circulating Soluble Leptin Receptor Levels By Gender, Adiposity, Sex Steroids, and Leptin. Diabetes, 2002, 51, 2105-2112.	0.6	225
436	Effects of Acute and Chronic Administration of the Melanocortin Agonist MTII in Mice With Diet-Induced Obesity. Diabetes, 2002, 51, 1337-1345.	0.6	190
437	Leptin in Relation to Growth and Developmental Processes in the Fetus. Seminars in Reproductive Medicine, 2002, 20, 123-130.	1.1	38
438	Leptin and reproduction: a review. Fertility and Sterility, 2002, 77, 433-444.	1.0	515
439	The role of leptin and hypothalamicneuropeptides in energy homeostasis: Update on leptin in obesity. Growth Hormone and IGF Research, 2001, 11, S85-S89.	1.1	23
440	Cord Blood Leptin and Insulin-Like Growth Factor Levels are Independent Predictors of Fetal Growth. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 935-938.	3.6	168
441	The Q223R Polymorphism of the Leptin Receptor Gene Is Significantly Associated with Obesity and Predicts a Small Percentage of Body Weight and Body Composition Variability. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4434-4439.	3.6	214
442	Serum leptin levels are higher but are not independently associated with severity or mortality in the multiple organ dysfunction/systemic inflammatory response syndrome: a matched case control and a longitudinal study. Clinical Endocrinology, 2001, 54, 225-233.	2.4	39
443	Leptin and the hypothalamic-pituitary regulation of the gonadotropin-gonadal axis. Pituitary, 2001, 4, 87-92.	2.9	95
444	Synchronicity of Frequently Sampled Thyrotropin (TSH) and Leptin Concentrations in Healthy Adults and Leptin-Deficient Subjects: Evidence for Possible Partial TSH Regulation by Leptin in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3284-3291.	3.6	199
445	Cord Blood Leptin and Insulin-Like Growth Factor Levels are Independent Predictors of Fetal Growth. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 935-938.	3.6	59
446	The Q223R Polymorphism of the Leptin Receptor Gene Is Significantly Associated with Obesity and Predicts a Small Percentage of Body Weight and Body Composition Variability. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4434-4439.	3.6	50
447	Hormonal Predictors of Prostate Cancer: A Meta-Analysis. Journal of Clinical Oncology, 2000, 18, 847-847.	1.6	273
448	Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. International Journal of Cancer, 2000, 87, 118-121.	5.1	65
449	Endogenous risk factors for childhood leukemia in relation to the IGF system (Greece). The Childhood Haematologists-Oncologists Group. Cancer Causes and Control, 2000, 11, 765-771.	1.8	21
450	Differential expression of hypothalamic neuropeptides in the early phase of diet-induced obesity in mice. American Journal of Physiology - Endocrinology and Metabolism, 2000, 279, E838-E845.	3.5	186

#	Article	IF	Citations
451	Decreased Serum Leptin in Bulimia Nervosa1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4511-4514.	3.6	63
452	Leptin as a Therapeutic Agentâ€"Trials and Tribulations. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4000-4002.	3.6	97
453	Role of Leptin in Reproduction. Annals of the New York Academy of Sciences, 2000, 900, 174-183.	3.8	198
454	Hormonal, Lifestyle, and Dietary Factors in Relation to Leptin among Elderly Men. Annals of Nutrition and Metabolism, 1999, 43, 23-29.	1.9	33
455	Cardiovascular Abnormalities in Transgenic Mice With Reduced Brown Fat. Circulation, 1999, 100, 2177-2183.	1.6	49
456	Cord blood leptin concentrations in relation to intrauterine growth. Clinical Endocrinology, 1999, 50, 177-183.	2.4	64
457	Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia. International Journal of Cancer, 1999, 80, 494-496.	5.1	53
458	Leptin in relation to carcinomaIn situ of the breast: A study of pre-menopausal cases and controls. International Journal of Cancer, 1999, 80, 523-526.	5.1	116
459	IGF-I and IGF-II in relation to colorectal cancer. International Journal of Cancer, 1999, 83, 15-17.	5.1	153
460	Leptin in renal failure. , 1999, 9, 122-125.		6
461	Dietary factors in relation to rheumatoid arthritis: a role for olive oil and cooked vegetables?. American Journal of Clinical Nutrition, 1999, 70, 1077-1082.	4.7	148
462	Dietary Fat and Carbohydrates Are Independently Associated With Circulating Insulin-Like Growth Factor 1 and Insulin-Like Growth Factorâ€"Binding Protein 3 Concentrations in Healthy Adults. Journal of Clinical Oncology, 1999, 17, 3291-3298.	1.6	113
463	Age, Sex, and Smoking Are Predictors of Circulating Insulin-Like Growth Factor 1 and Insulin-Like Growth Factorâ€"Binding Protein 3. Journal of Clinical Oncology, 1999, 17, 813-813.	1.6	91
464	The Role of Leptin in Human Obesity and Disease: A Review of Current Evidence. Annals of Internal Medicine, 1999, 130, 671.	3.9	490
465	Insulinâ€like growth factorâ€I and binding proteinâ€3 in relation to childhood leukaemia. International Journal of Cancer, 1999, 80, 494-496.	5.1	3
466	Leptin: in search of role(s) in human physiology and pathophysiology. Clinical Endocrinology, 1998, 49, 551-567.	2.4	163
467	Zinc May Regulate Serum Leptin Concentrations in Humans. Journal of the American College of Nutrition, 1998, 17, 270-275.	1.8	144
468	Circulating Insulin Concentrations, Smoking, and Alcohol Intake Are Important Independent Predictors of Leptin in Young Healthy Men. Obesity, 1998, 6, 179-186.	4.0	105

#	Article	IF	Citations
469	Sex Differences in Circulating Human Leptin Pulse Amplitude: Clinical Implications1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4140-4147.	3.6	154
470	Insulin-Like Growth Factor-I in Relation to Premenopausal Ductal Carcinoma in Situ of the Breast. Epidemiology, 1998, 9, 570-573.	2.7	180
471	Gender differences in leptin levels during puberty are related to the subcutaneous fat depot and sex steroids. American Journal of Physiology - Endocrinology and Metabolism, 1998, 275, E543-E551.	3.5	73
472	Short-Term Hyperthyroidism Has No Effect on Leptin Levels in Man1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 497-499.	3.6	79
473	Effect of Birth Weight and Maternal Smoking on Cord Blood Leptin Concentrations of Full-Term and Preterm Newborns1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2856-2861.	3.6	96
474	Leptin Concentrations in the Polycystic Ovary Syndrome1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1687-1691.	3.6	156
475	Leptin Concentrations in Relation to Body Mass Index and the Tumor Necrosis Factor-Î± System in Humans1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3408-3413.	3.6	226
476	A Longitudinal Assessment of Hormonal and Physical Alterations during Normal Puberty in Boys. V. Rising Leptin Levels May Signal the Onset of Puberty1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1066-1070.	3.6	352
477	Cerebrospinal Fluid Leptin in Anorexia Nervosa: Correlation with Nutritional Status and Potential Role in Resistance to Weight Gain1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1845-1851.	3.6	185
478	Human leptin levels are pulsatile and inversely related to pituitaryâ€“ardenal function. Nature Medicine, 1997, 3, 575-579.	30.7	637
479	Serum steroids in relation to prostate cancer risk in a case-control study (Greece). Cancer Causes and Control, 1997, 8, 632-636.	1.8	28
480	Role of leptin in the neuroendocrine response to fasting. Nature, 1996, 382, 250-252.	27.8	2,865